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Prostate biopsyIndication for prostate biopsy is presently mainly based on prostate-speciﬁc antigen (PSA) serum levels and
digital-rectal examination (DRE). In view of the unsatisfactory accuracy of these two diagnostic exams,
research has focused on novel markers to improve pre-biopsy prostate cancer detection, such as phi and PCA3.
The purpose of this prospective study was to assess the diagnostic accuracy of phi and PCA3 for prostate
cancer using biopsy as gold standard.
Phi index (Beckman coulter immunoassay), PCA3 score (Progensa PCA3 assay) and other established
biomarkers (tPSA, fPSA and %fPSA) were assessed before a 18-core prostate biopsy in a group of 251 subjects
at their ﬁrst biopsy.
Values of %p2PSA and phi were signiﬁcantly higher in patients with PCa compared with PCa-negative group
(pb0.001) and also compared with high grade prostatic intraepithelial neoplasia (HGPIN) (pb0.001). PCA3
score values were signiﬁcantly higher in PCa compared with PCa-negative subjects (pb0.001) and in HGPIN
vs PCa-negative patients (pb0.001). ROC curve analysis showed that %p2PSA, phi and PCA3 are predictive of
malignancy.
In conclusion, %p2PSA, phi and PCA3 may predict a diagnosis of PCa in men undergoing their ﬁrst prostate
biopsy. PCA3 score is more useful in discriminating between HGPIN and non-cancer.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Results of prostate biopsies are currently dichotomized in presence
and absence of cancer. Biopsy outcomes that are neither benign nor
malignant are diagnosed, in most of cases, as high grade prostatic
intraepithelial neoplasia (HGPIN) or atypical small acinar proliferationostate cancer antigen 3; PSA,
on; tPSA, total PSA; fPSA, free
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2), doi:10.1016/j.cca.2012.04(ASAP). Among these, HGPIN shares morphologic and genetic changes
with cancer, but do not invade the basement membrane of prostatic
gland [1]. The incidence of isolatedHGPIN on needle biopsy ranges from
0 to 24.6% and the risk of cancer on re-biopsy is 22% [2,3].
PSA serum level and DRE are the main tools to select subjects for
prostate biopsy [4], even if there are assay-dependent variations in PSA
[5] and inter-observer variability of DRE [6]. Several studies address this
issue and new biomarkers that may improve the detection of prostate
cancer (PCa) have been proposed [7,8]. Among these, prostate health
index (phi) and prostate cancer antigen 3 (PCA3) appear extremely
promising [9].
PCA3 is a urine biomarker useful to select candidates for a repeat
biopsy strategy [10–12]. In ﬁrst biopsy, previous report indicated that
PCA3 is able to improve PSA diagnostic performance [13]. We
previously reported that PCA3 can aid in predicting cancer in patients
with PSA levels in the “grey” area [14].e: prostate health index (phi) and prostate cancer antigen 3 (PCA3)
.017
Table 1
Clinical characteristics of study population.
BPH
n=67
HGPIN
n=36
PCa
n=48
All
n=151
Characteristics (44%) (24%) (32%)
Prostate volume (cc)
≤40 51 (76) 24 (67) 37 (77) 112 (74)
>40 16 (23) 12 (33) 11 (23) 39 (26)
PSAd (ng/ml/cc)
≤0.15 40 (59) 23 (64) 22 (46) 85 (56)
>0.15 27 (40) 13 (36) 26 (54) 66 (44)
PSA (ng/ml)
0–4 13 (19) 9 (25) 3 (6) 25 (16)
4.1–10 43 (64) 25 (69) 33 (69) 101 (67)
10.1–20 11 (16) 2 (5) 12 (25) 25 (16)
%f-PSA
1–10 4 (6) 1 (3) 12 (25) 17 (11)
10.1–15 10 (15) 5 (14) 12 (25) 27 (18)
15.1–20 21 (31) 6 (17) 12 (25) 39 (26)
>20 32 (48) 24 (67) 12 (25) 68 (45)
Biopsy Gleason score
b7 / / 21 (44) /
≥7 / / 27 (56) /
Clinically signiﬁcant / / 42 (87) /
Clinically insigniﬁcant / / 6 (13) /
2 M. Ferro et al. / Clinica Chimica Acta xxx (2012) xxx–xxxRecently, the phi index, resulting from the combination of total
PSA (tPSA), fPSA and [−2]proPSA (p2PSA) was developed [15].
ProPSA represents a cancer-associated form of free PSA detectable in
the circulation [16]. Preliminary studies showed that p2PSA, %p2PSA
and phi are higher in malignant than in benign prostatic conditions
and their use can signiﬁcantly improve cancer detection with respect
to other biomarkers such as tPSA and f/t PSA ratio [15–17].
Aim of this prospective study was to assess accuracy of phi and
PCA3 to predict benign, malignant and HGPIN diagnosis in men
undergoing ﬁrst biopsy.
2. Materials and methods
2.1. Study design
Between May and December 2010, two hundred and ﬁfty male
subjects were referred to a major oncologic center (IRCCS Fondazione
G. Pascale, Naples, Italy) to undergo ﬁrst prostate biopsy. They
provided informed consent and were screened to be enrolled in a
prospective study. Hospital ethics committee was obtained and
Standards for the Reporting of Diagnostic Accuracy guidelines were
followed.
Blood specimens were collected according to predetermined
standard operating procedure [18]. Among these, only those meeting
eligibility criteria according to the study protocol were ultimately
enrolled: age over 50 years, no prior prostate surgery and biopsy, no
bacterial acute or chronic prostatitis, no use of 5-α reductase
inhibitors in the previous six months, PSA values included between
2 and 20 ng/ml, negative digital rectal examination (DRE), availability
of serum and urine samples and corresponding clinical data.
2.2. Specimens and laboratory analysis
Whole blood was allowed to clot before serum was separated by
centrifugation. Serum aliquots were stored at −80 °C until samples
were processed, according to Semjonow et al. [19]. Specimens were
analyzed in blinded fashion for PSA, fPSA and p2PSA by Access2
Immunoassay System analyzer (Beckman Coulter, Brea, CA, USA).
First catch urine samples were collected following an attentive
DRE (three strokes per lobe) as described by Grospkopf et al. [20]
immediately before biopsy was performed; urine samples were
processed and tested to quantify PCA3-messenger RNA(mRNA) and
PSA-mRNA concentrations using the Progensa PCA3 assay (Gen-
Probe, San Diego, CA, USA). The PCA3 score was calculated as mRNA
PCA3/mRNA PSA×1000.
All patients underwent a 18-core transrectal-ultrasound (TRUS)
guided prostate biopsy according to a standardized scheme [21].
Primary and secondary Gleason scores were assigned by a single
genitourinary pathologist blinded to the biomarkers values, according
to the 2005 consensus conference of the International Society of
Urological Pathology deﬁnitions [22]. Patients diagnosed with high-
grade prostatic intraepithelial neoplasia (HGPIN) were compared to
benign and malignant biopsy outcome.
2.3. Study endpoints
The primary aim of the study was to compare the identifying
ability of PCa-negative, PCa-positive and HGPIN of Beckman coulter
phi [(p2PSA/fPSA)×√tPSA] and PCA3 score [(PCA3 mRNA/PSA
mRNA)×1000].
2.4. Statistical analysis
Statistical analyses were performed with the statistical computing
environment R (version 2.12.1; R Foundation for Statistical Comput-
ing, Vienna, Austria). For all analyses, we used two-sided tests, with pPlease cite this article as: Ferro M, et al, Predicting prostate biopsy outcom
are useful biomarkers, Clin Chim Acta (2012), doi:10.1016/j.cca.2012.04values less than 0·05 denoting statistical signiﬁcance. Results are
expressed as Median [Min–Max] for numeric variables and as
percentages for categorical factors.
The Kruskal–Wallis test was used to assess the presence of
differences among groups (no PCa, HGPIN and PCa); if the results
were signiﬁcant, multiple comparisons were made according to the
Mann–Whitney nonparametric procedure.
Diagnostic validity of the different biomarkers was evaluated by
ROC curve analysis. The diagnostic accuracy was measured using the
Area Under the Roc Curve (AUC). In order to reach a statistical power
(1-β) of 80% at a signiﬁcance level (α) of 5%, a total of 141 subjects
(47 with positive status and 94 with a negative status) were needed
to detect a difference between two correlated AUC of ±15% (when
this difference truly exists), assuming a sample allocation rate of 1/2
and a correlation between the two test variables of 0.4. The
evaluation of the statistical signiﬁcance of the difference between
two correlated AUC was carried out according to the DeLong method
[23] whenever the direction of the two testing variables was equal;
otherwise a bootstrap procedure was carried out with B=2000
bootstrap samples.
Multivariable statistical modeling to assess whether the synthesis
of several biomarkers into a diagnostic score would have produced a
signiﬁcant increase in their discriminatory ability was carried out
according to standard statistical practice [24,25].
3. Results
Overall, one hundred and ﬁfty-one patients met inclusion criteria
and were enrolled. Demographic and clinical characteristics of the
study population are listed in Table 1. HGPIN was found in 24% of
subjects, prostate biopsy-detected cancer in 32%, of which about 90%
were clinically signiﬁcant according to Epstein criteria, based on 1)
PSA density ≥0.15 ng/ml, 2) biopsy Gleason score >6, 3) the
presence of tumor in more than two cores, and 4) more than 50%
involvement by tumor in any single core [26].
As shown in Table 2 the median age (range) of the subjects
included in this study was 64.5±7.3 years. Mean age was not
signiﬁcantly different in cancer, pre-cancer and non-cancer groups.
Values of %p2PSA and phi were signiﬁcantly higher in patients with
PCa compared with PCa-negative group (median values: 1.86 vs 1.45
and 53.38 vs 36.21 respectively, pb0.001) and also compared withe: prostate health index (phi) and prostate cancer antigen 3 (PCA3)
.017
Table 2
Descriptive statistics of the analyzed variables.
No PCa HGPIN PCa All
Variable Median [range] Median [range] Median [range] Median [range] Kruskall Wallis p No Pca vs HGPIN No Pca vs PCa HGPIN vs PCa
Age (years) 64.0 [50–87] 66.5 [48–80] 66.0 [48–81] 64.5 [48–87] 0.054 n.s. n.s. n.s.
Prostate
volume (cc)
50 [20–200] 45 [25–80] 47 [15–84] 48 [15–200] 0.421 n.s. n.s. n.s.
PSA (ng/ml) 6.79 [2–20] 5.97 [3–17] 7.88 [4–20] 6.85 [2–20] 0.019 n.s. n.s. 0.005
fPSA (ng/ml) 1.25 [0.46–4.02] 1.37 [0.5–2.64] 1.15 [0.27–4.43] 1.21 [0.27–4.43] 0.537 n.s. n.s. n.s.
p2PSA (pg/ml) 17.46 [7.54–76.93] 18.55 [6.01–46.33] 20.73 [3.75–86.3] 18.88 [3.75–86.3] 0.155 n.s. n.s. n.s.
% p2PSA 1.45 [0.43–4.17] 1.64 [0.93–3.44] 1.86 [0.26–5.05] 1.63 [0.26–5.05] b0.001 n.s. b0..001 b0.001
% fPSA 19.36 [7.6–50] 22.23 [5.5–45] 15.41 [4.8–38.9] 19.20 [4.8–50] 0.001 n.s. 0.004 0.001
Phi 36.21
[14.02–142.77]
36.82
[19.05–106.04]
53.38
[5.05–162.89]
40.66
[5.05–162.89]
b0.001 n.s. b0.001 b0.001
PCA3 28.0 [2–257] 54.5 [7–254] 57.0 [3–339] 47.0 [2–339] b0.001 b0.001 b0.001 n.s.
3M. Ferro et al. / Clinica Chimica Acta xxx (2012) xxx–xxxHGPIN (median values: 1.86 vs 1.64 and 53.38 vs 36.82 respectively,
pb0.001) (Fig. 1A–B). %fPSA values were signiﬁcantly lower in PCa
patients compared with non-malignant conditions and with HGPIN
(median values: 15.4 vs 19.36 and 15.4 vs 22.23, p=0.004 and
pb0.001, respectively) (Fig. 1C). PCA3 score values were signiﬁcantly
higher in malignant compared with PCa-negative group (medianFig. 1. (A–D). Median values of p2PSA, Phi, %fPSA and PCA3 score in study population: c
Please cite this article as: Ferro M, et al, Predicting prostate biopsy outcom
are useful biomarkers, Clin Chim Acta (2012), doi:10.1016/j.cca.2012.04values: 57 vs 28, pb0.001) and in HGPIN vs benign conditions
(median values: 54.5 vs 28, pb0.001) (Fig. 1D). Differently from phi,
PCA3 score of PCa-positive patients was not signiﬁcantly different
from HGPIN diagnosed group.
ROC curve analysis (Fig. 2) showed that %p2PSA, phi and PCA3 are
good indicators ofmalignancy (AUCs=0.73, 0.77 and 0.71, respectively).omparison among PCa-negative, pre-neoplastic condition and PCa-positive patients.
e: prostate health index (phi) and prostate cancer antigen 3 (PCA3)
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Fig. 2. ROC curve analysis comparing discriminating ability between benign and
malignant condition of fPSA, p2PSA, %p2PSA, %fPSA, phi and PCA3 with respective
AUCs.
4 M. Ferro et al. / Clinica Chimica Acta xxx (2012) xxx–xxxPhi had the highest AUC, but the difference between phi and PCA3 was
not statistically signiﬁcant (p=0.368). On the contrary, signiﬁcant
differences in AUCs were found between phi and both fPSA and p2PSA
(p=0.006 and pb0.001 respectively) and between PCA3 and fPSA
(p 0.036). Also %p2PSA showed a better discriminatory performance
with respect to both fPSA (p=0.011) and p2PSA (p=0.009) (Fig. 2). As
shown in Table 3 the optimal cut-point for phi was 38.7, corresponding
to 85% sensitivity and 61% speciﬁcity, whereas the optimal cut-point for
PCA3 was 32.5, corresponding to 81% sensitivity and 57% speciﬁcity. To
achieve 90% speciﬁcity, cut-pointwas 63.5 for phi and 86 for PCA3, but at
the cost of a lower sensitivity which decreased to 36% and 32%,
respectively. A speciﬁcity of 80%, was associated with a cut-point of
50.2 for phi and 73 for PCA3, corresponding to a sensitivity of 60% and
43%, respectively.
Multivariable analysis produced no signiﬁcant model to improve
the performance of the single biomarker (data not shown).4. Discussion
The controversy on PCa screening [27] provided an ideal
environment in which to develop tools that may assist in predicting
who may have PCa. Such predictive model would have implications
when counseling patients whether or not to have a biopsy in the
ﬁrst instance.
%p2PSA and phi represent early-evaluated tests for PCa detection in
patients with tPSA between 2 and 10 ng/ml [28], whereas PCA3 score
has been well recognized as good indicator of cancer on repeat biopsy
[11,12,29].Table 3
Optimal cut-point of the analyzed variables.
Optimal
Cutpoint Sensitivity [95% C.I.] Speciﬁcity [95% C.I.]
fPSA ≤1.6 0.81 [0.7–0.91] 0.36 [0.24–0.46]
p2PSA ≥18.37 0.66 [0.53–0.79] 0.57 [0.45–0.69]
% p2PS ≥1.7 0.70 [0.57–0.83] 0.70 [0.58–0.81]
% fPSA ≤13.7 0.49 [0.34–0.64] 0.85 [0.76–0.93]
phi ≥38.7 0.85 [0.74–0.94] 0.61 [0.49–0.72]
PCA3 ≥32.50 0.81 [0.68–0.91] 0.57 [0.45–0.69]
Please cite this article as: Ferro M, et al, Predicting prostate biopsy outcom
are useful biomarkers, Clin Chim Acta (2012), doi:10.1016/j.cca.2012.04Some authors compared the performance of PCA3 with those of
PSA as ﬁrst-line diagnostic test. Ploussard et al. reported that high
PCA3 score was a good indicator of positive re-biopsy, especially in
the group of patients with f/t PSA ratio>10% [30]. Moreover, the
authors noted that PCA3, contrary to PSA and f/t PSA ratio, was not
associated with prostate volume, age or stage, making PCA3 a
potentially good complementary marker to PSA and its molecular
forms.
To date, a head-to-head comparison between phi and PCA3 has
yet to be reported. Such comparison could be very interesting in order
to establish which the best test as predictor of biopsy outcome is and
whether the combination of the two biomarkers improves PCa
detection.
In the current study we examined the diagnostic performance of
fPSA, p2PSA, phi and PCA3 in the tPSA range 2–20 ng/ml. We found
that %p2PSA, phi and PCA3 were signiﬁcantly higher and %fPSA was
signiﬁcantly lower in cancer than in noncancer. Furthermore, statistical
analysis indicated that phi values, as %p2PSA and %fPSA, unlike PCA3
score, were signiﬁcantly different in HGPIN conditions and cancer. PCA3
score was signiﬁcantly higher in HGPIN than in PCa-negative group.
Interestingly, most part of the analyzed tumors was clinically signiﬁcant.
ROC curve analysis showed that %p2PSA, phi and PCA3 outperformed
fPSA, %fPSA and p2PSA. Of note, the AUCs of these biomarkers were not
signiﬁcantly different, indicating comparable ability to discriminate
benign from malignant condition.
A relevant ﬁnding of this study was that men with HGPIN show
comparable PCA3 scores as men with PCa, differently from phi. These
data agree with previous reports showing that the discriminative
performance of PCA3 score is lower between HGPIN and PCa [11,31].
Moreover, we found that PCA3 scores were signiﬁcantly higher in
HGPIN than in PCa-negative group. This ﬁnding probably reﬂects
early molecular changes in a presumptive premalignant lesion [32]. In
addition, HGPIN are strong risk factor for PCa in re-biopsy [2,3], thus
some of our patients diagnosed as HGPIN may actually have PCa.
According to previous report, this result supports that low PCA3 score
is a good indicator of benign lesion [33]. To our knowledge, this is the
ﬁrst report indicating the association between phi and HGPIN biopsy
outcome. Interestingly, our results are consistent with recent study
showing that the intensity of [−2]pro-PSA staining at immuno-
chemistry progressively increased in benign, HGPIN and neoplastic
specimens [34].
The choice of evaluating HGPIN was made as it represents the only
other category of biopsy outcome thatmay be realistically considered as
pre-malignant condition, according to virtually all available evidence
[35,36].
Despite the strength of a prospective observational study
including patients with available data of both phi and PCA3 and
with centrally pathological evaluation, our study examined a small
number of cases. Therefore larger studies are needed to address several
important questions such as a) the comparison of the single biomarker
and the usefulness of the “combined” one; b) the identiﬁcation of
valuable cut-off values to be used in clinical practice; c) the ability of
phi and PCA3 alone or in combination to predict clinically signiﬁcant
PCa.90% speciﬁcity 80% speciﬁcity
Cutpoint Sensitivity [95% C.I.] Cutpoint Sensitivity [95% C.I.]
≤0.6 0.13 [0.04–0.28] ≤0.8 0.21 [0.11–0.43]
≥36.0 0.23 [0.11–0.38] ≥28.4 0.32 [0.17–0.49]
≥2.5 0.38 [0.17–0.6] ≥2.1 0.51 [0.36–0.72]
≤11.4 0.34 [0.15–0.57] ≤14.4 0.49 [0.32–0.64]
≥63.5 0.36 [0.13–0.62] ≥50.2 0.60 [0.38–0.79]
≥86.0 0.32 [0.04–0.49] ≥73.0 0.43 [0.26–0.64]
e: prostate health index (phi) and prostate cancer antigen 3 (PCA3)
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5M. Ferro et al. / Clinica Chimica Acta xxx (2012) xxx–xxxIn summary, %p2PSA, fPSA, phi and PCA3 may be useful predictors
of PCa in ﬁrst biopsy. In addition, PCA3 seems to discriminate HGPIN
from non cancer condition.
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